• D. R. HarperEmail author
Living reference work entry


As the ongoing crisis of antimicrobial resistance (AMR) threatens to bring an end to the era of the routine control of bacterial diseases, there is great interest in developing other approaches to controlling such infections. One of the oldest of these, the use of bacteriophages (viruses that can target and destroy bacteria) as therapeutic agents, is experiencing a resurgence of interest and is now considered a promising approach to countering AMR. First developed 100 years ago, this approach, known as phage therapy, was set aside in Western Europe and the USA when the use of chemical antibiotics became widespread. Now, the pressing need for new ways to control such resistant bacteria is resulting in progress in developing phage therapy, alongside a range of technologies based around bacteriophages, in medicine, and elsewhere.

Bacteriophages: Biology, Technology, and Therapy is intended to cover all aspects of work with bacteriophages, from basic biology to clinical trials and from early history to nanotechnology.


  1. Abedon ST, Thomas-Abedon C, Thomas A, Mazure H (2011) Bacteriophage prehistory: is or is not Hankin, 1896, a phage reference? Bacteriophage 1:174–178CrossRefPubMedPubMedCentralGoogle Scholar
  2. Barber KE, Ireland CE, Bukavyn N, Rybak MJ (2014) Observation of “seesaw effect” with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther 3:35–43CrossRefPubMedPubMedCentralGoogle Scholar
  3. Brown JC (2003) Virology. In: The encyclopedia of life sciences. Wiley, Chichester.
  4. Bruttin A, Brüssow H (2005) Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49:2874–2878CrossRefPubMedPubMedCentralGoogle Scholar
  5. Cairns J, Stent GS, Watson JD (eds) (2007) Phage and the origins of molecular biology. CSHL Press, New YorkGoogle Scholar
  6. CDC (2013) Antibiotic resistance threats in the United States, 2013.
  7. Chain E, Florey HW, Adelaide MB et al (1940) Penicillin as a chemotherapeutic agent. Clin Orthop Relat Res 295:3–7Google Scholar
  8. Chan M (2016) WHO Director-General briefs UN on antimicrobial resistance.
  9. Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock REW, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Ólafsdóttir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P, Rex JH (2016) Alternatives to antibiotics–a pipeline portfolio review. Lancet Infectious Diseases 16: 239–251Google Scholar
  10. d’Herelle F (1917) Sur un microbe invisible antagonistic des bacilles dysenteriqes. C R Acad Sci Paris 165:373–375Google Scholar
  11. d’Herelle F (1919) Sur le role du microbe bacteriophage dans la typhose aviare. C R Acad Sci Paris 169:932–934Google Scholar
  12. Duckworth DH (1976) Who discovered bacteriophage? Bacteriol Rev 40:793–802PubMedPubMedCentralGoogle Scholar
  13. Eaton MD, Bayne-Jones S (1934) Bacteriophage therapy: review of the principles and results of the use of bacteriophage in the treatment of infections. JAMA 103:1769–1776; 1847–1853; 1934–1939CrossRefGoogle Scholar
  14. Harper DR (2011) Viruses: Biology, Applications and Control. Garland Science, New YorkGoogle Scholar
  15. Harper DR, Enright MC (2011) Bacteriophages for the treatment of Pseudomonas aeruginosa infections. J Appl Microbiol 111:1–7Google Scholar
  16. Harper DR, Burrowes BH, Kutter EM (2014a) Bacteriophage: therapeutic uses. In: The encyclopedia of life sciences. Wiley, Chichester.
  17. Harper DR, Parracho HMRT, Walker J et al (2014b) Bacteriophages and biofilms. Antibiotics 3:270–284CrossRefPubMedCentralGoogle Scholar
  18. Harper DR, McConville M, Anderson FJ, Enright MC (2015) Antimicrobial phages. In: Tang YW et al (eds) Molecular medical microbiology, 2nd edn. Elsevier, San DiegoGoogle Scholar
  19. Hiltunen T, Virta M, Laine AL (2017) Antibiotic resistance in the wild: an eco-evolutionary perspective. Philos Trans R Soc Lond Ser B Biol Sci 372:20160039CrossRefGoogle Scholar
  20. Hobman JL, Crossman LC (2015) Bacterial antimicrobial metal ion resistance. J Med Microbiol 64:471–497CrossRefPubMedGoogle Scholar
  21. Howie J (1986) Penicillin: 1929–40. Br Med J 293:158–159CrossRefGoogle Scholar
  22. Krueger AP, Scribner EJ (1941) The bacteriophage: its nature and its therapeutic use. JAMA 116:2160–2167CrossRefGoogle Scholar
  23. Lachapelle J-M, Castel O, Casado AF et al (2013) Antiseptics in the era of bacterial resistance: a focus on povidone iodine. Clin Pract 10:579–592CrossRefGoogle Scholar
  24. Lewis S (1925) Arrowsmith. Harcourt Brace and Company, New YorkGoogle Scholar
  25. Mathews CK (2015) Bacteriophage T4. In: eLS. John Wiley & Sons Ltd, Chichester.
  26. Marza JA, Soothill JS, Boydell P, Collyns TA (2006) Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 32:644–646CrossRefPubMedGoogle Scholar
  27. McCallin S, Sarker SA, Barretto C et al (2013) Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology 443:187–196CrossRefPubMedGoogle Scholar
  28. Neu HC (1992) The crisis in antibiotic resistance. Science 257:1064–1073CrossRefPubMedGoogle Scholar
  29. Pirnay JP, De Vos D, Verbeken G et al (2011) The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm Res 28:93493–93497CrossRefGoogle Scholar
  30. Rhoads DD, Wolcott RD, Kuskowski MA et al (2009) Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 18:240–243CrossRefGoogle Scholar
  31. Rohwer F, Edwards R (2002) The phage proteomic tree: a genome-based taxonomy for phage. J Bacteriol 184:4529–4535CrossRefPubMedPubMedCentralGoogle Scholar
  32. Rose T, Verbeken G, Vos DD et al (2014) Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma 4:66–73PubMedPubMedCentralGoogle Scholar
  33. Ruska E (1986) Nobel lecture. The development of the electron microscope and of electron microscopy.
  34. Sarker SA, Sultana S, Reuteler G et al (2016) Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4:124–137CrossRefPubMedPubMedCentralGoogle Scholar
  35. Schooley RT, Biswas B, Gill JJ et al (2017) Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 61:e00954–e00917CrossRefPubMedPubMedCentralGoogle Scholar
  36. Smith HW, Huggins MB (1982) Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 128:307–318PubMedGoogle Scholar
  37. Smith HW, Huggins MB (1983) Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 129:2659–2675PubMedGoogle Scholar
  38. Smith HW, Huggins MB, Shaw KM (1987) The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol 133:1111–1126PubMedGoogle Scholar
  39. Spellberg B, Taylor-Blake B (2013) On the exoneration of Dr. William H. Stewart: debunking an urban legend. Infect Dis Poverty 2:3CrossRefPubMedPubMedCentralGoogle Scholar
  40. Streptomycin in Tuberculosis Trials Committee (1948) Streptomycin treatment of pulmonary tuberculosis. A Medical Research Council investigation. Br Med J 2:769–782CrossRefGoogle Scholar
  41. Sukkar E (2013) Why are there so few antibiotics in the research and development pipeline? Pharm J 291:520Google Scholar
  42. Twort FW (1915) An investigation on the nature of ultramicroscopic viruses. Lancet 1915:1241CrossRefGoogle Scholar
  43. Ventola CL (2015) The antibiotic resistance crisis. Part 1: causes and threats. P T 40:277–283PubMedPubMedCentralGoogle Scholar
  44. WHO (2017) WHO publishes list of bacteria for which new antibiotics are urgently needed.
  45. Wright A, Hawkins C, Anggard EA, Harper DR (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clinical Otolaryngology 34: 349–357Google Scholar
  46. Yang SJ, Xiong YQ, Boyle-Vavra S et al (2010) Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the “seesaw effect”). Antimicrob Agents Chemother 54:3161–3169CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Evolution BiotechnologiesSharnbrookUK

Personalised recommendations